Merck, Threshold Shake Hands in $550M Cancer Collaboration
Stock in Threshold Pharmaceuticals Inc. surged more than 131 percent on news that it signed a deal with Merck KGaA valued at up to $550 million to develop and commercialize Threshold's cancer candidate, TH-302.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter